17 results
10-K
2020 FY
RPTX
Repare Therapeutics Inc
4 Mar 21
Annual report
5:25pm
inhibitors in preclinical development. The intensity of trials with ATR inhibitors as monotherapy and in combination with immune-oncology compounds … and telecommunication and electrical failures. Cyber-attacks are increasing in their frequency, sophistication, and intensity, and have become
10-Q
iab91ggj
13 Aug 20
Quarterly report
4:12pm
S-1
jc9 pj4feyb6
29 May 20
IPO registration
5:26pm
DRS
sdwbubebem2pyuv1o03t
6 Apr 20
Draft registration statement
12:00am
424B4
x4odj
19 Jun 20
Prospectus supplement with pricing info
4:38pm
S-1/A
hgta2wr
15 Jun 20
IPO registration (amended)
6:18am
DRS/A
1yn7dn
12 May 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next